Amgen Inc. / BioVex Group, Inc.

Metastatic Melanoma

Disease Overview

Metastatic melanoma is the most lethal form of skin cancer, characterized by spread of melanocytic tumor cells to distant organs. Before the 2011 BioVex acquisition, treatment options were limited to dacarbazine chemotherapy and high-dose IL-2 with poor response rates. Stage IV melanoma is highly immunogenic, making it an attractive target for immunotherapy approaches.

Competitive Landscape

When Amgen acquired BioVex in March 2011 for $425M upfront plus $575M in milestones, the metastatic melanoma landscape was on the cusp of revolution. Yervoy (ipilimumab, BMS, anti-CTLA-4) had received FDA approval that same month, becoming the first agent to extend overall survival in stage IV melanoma. Vemurafenib (Zelboraf, Roche/Plexxikon, BRAF V600E inhibitor) followed in August 2011, and the PD-1 era arrived with Keytruda (pembrolizumab, Merck, 2014) and Opdivo (nivolumab, BMS, 2014). OncoVEX/T-VEC (talimogene laherparepvec, an HSV-1 oncolytic virus engineered to delete ICP34.5/ICP47 and express GM-CSF) was Phase 3 at deal time and ultimately received FDA approval in October 2015 as Imlygic — the first oncolytic virus approved in the US. Imlygic's commercial trajectory has been modest as monotherapy (intratumoral injection requirement, head-to-head pressure from systemic checkpoint inhibitors), but the asset retains scientific significance as a category-defining oncolytic immunotherapy and continues to be studied in PD-1 combination regimens. Nature Reviews Drug Discovery contemporaneous coverage characterized the deal as Amgen's bet on a then-unproven oncolytic virus class.